SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
Open accessPublished version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Introduction: Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on public health and social measures (PHSM) and vaccine strategy. Methods: We searched for seroprevalence studies conducted in Africa published 1 January 2020–30 December 2021 in Medline, Embase, Web of Science and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity seroprevalence protocol. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO.PROSPERO: CRD42020183634. Results: We identified 56 full texts or early results, reporting 153 distinct seroprevalence studies in Africa. Of these, 97 (63%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0% (95% CI 1.0% to 9.2%) in April–June 2020 to 65.1% (95% CI 56.3% to 73.0%) in July–September 2021. The ratios of seroprevalence from infection to cumulative incidence of confirmed cases was large (overall: 100:1, ranging from 18:1 to 954:1) and steady over time. Seroprevalence was highly heterogeneous both within countries—urban versus rural (lower seroprevalence for rural geographic areas), children versus adults (children aged 0–9 years had the lowest seroprevalence)—and between countries and African subregions. Conclusion: We report high seroprevalence in Africa suggesting greater population exposure to SARS-CoV-2 and potential protection against COVID-19 severe disease than indicated by surveillance data. As seroprevalence was heterogeneous, targeted PHSM and vaccination strategies need to be tailored to local epidemiological situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Munn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131
A global database of COVID-19 vaccinations
Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01122-8 · Cited by 1,974
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · cited 1×
“58 SARS- CoV-2 seroprevalence is high and heterogenous in Africa, suggesting greater population exposure to SARS- CoV-2 and potential protection against COVID-19 severe disease than has been previously indicated by confirmed case data and vaccine coverage.”
Evidence for antibody as a protective correlate for COVID-19 vaccines
Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R., Dull, P., & Plotkin, S. A. (2021) · doi:10.1101/2021.03.17.20200246 · Cited by 870
How are systematic reviews of prevalence conducted? A methodological study
on behalf of the Prevalence Estimates Reviews – Systematic Review Methodology Group (PERSyst), Borges Migliavaca, C., Stein, C., Colpani, V., Barker, T. H., Munn, Z., & Falavigna, M. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-00975-3 · Cited by 359
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252617 · Cited by 246
Self-citationSerological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Chen, X., Chen, Z., Azman, A. S., Deng, X., Sun, R., Zhao, Z., Zheng, N., Chen, X., Lu, W., Zhuang, T., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00026-7 · Cited by 239
Diop, B. Z., Ngom, M., Pougué Biyong, C., & Pougué Biyong, J. N. (2020) · BMJ Global Health · doi:10.1136/bmjgh-2020-002699 · Cited by 207
Mandolo, J., Msefula, J., Henrion, M. Y. R., Brown, C., Moyo, B., Samon, A., Moyo-Gwete, T., Makhado, Z., Ayres, F., Motlou, T., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02187-y · Cited by 61
Research works printed but not linked: 27
- 10.1136/bmj-2021-068123 · DOI
- Cohen, 2021, SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021, medRxiv
- Chisale, 2022, Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: a systematic review and meta-analysis, Rev Med Virol, 32, 10.1002/rmv.2271 · DOI
- Bergeri, 2022, Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic, Influenza Other Respir Viruses, 16, 7, 10.1111/irv.12915 · DOI
- Bergeri I , Whelan M , Ware H . Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022. medRxiv 2022.doi:https://doi.org/10.1101/2021.12.14.21267791 · DOI · Paper page
- 10.1016/j.jclinepi.2020.06.039 · DOI · Paper page
- Bobrovitz N , Noel KC , Li Z . SeroTracker-RoB: an approach to automating reproducible risk of bias assessment of seroprevalence studies. medRxiv 2022.doi:https://doi.org/10.1101/2021.11.17.21266471 · DOI
- 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E · DOI · Paper page
- Karamagi, 2021, Towards universal health coverage in the WHO African Region: assessing health system functionality, incorporating lessons from COVID-19, BMJ Glob Health, 6, 10.1136/bmjgh-2020-004618 · DOI
- 10.1128/JCM.00767-21 · DOI
- Gudina, 2021, Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities, Lancet Glob Health, 9, e1517, 10.1016/S2214-109X(21)00386-7 · DOI
- Barrie, 2021, SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey, medRxiv
- Bobrovitz N , Arora RK , Yan T . Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys. medRxiv 2020:20097451. · DOI · Paper page
- Arora, 2021, SeroTracker: a global SARS-CoV-2 seroprevalence dashboard, Lancet Infect Dis, 21, e75, 10.1016/S1473-3099(20)30631-9 · DOI · Paper page
- Borrega, 2021, Cross-reactive antibodies to SARS-CoV-2 and MERS-CoV in pre-covid-19 blood samples from Sierra leoneans, Viruses, 13, 10.3390/v13112325 · DOI
- 10.1016/j.ijid.2020.10.104 · DOI · Paper page
- Steinhardt, 2021, Cross-reactivity of two SARS-CoV-2 serological assays in a setting where Malaria is endemic, J Clin Microbiol, 59, 10.1128/JCM.00514-21 · DOI
- 10.1016/j.nmni.2020.100817 · DOI
- 10.7554/eLife.70330 · DOI
- 10.1038/s41590-021-01089-8 · DOI · Paper page
- 10.1186/s41118-021-00130-w · DOI
- 10.1007/s12646-021-00607-w · DOI
- 10.2471/BLT.20.265942 · DOI
- 10.5588/pha.20.0069 · DOI
- 10.1016/j.vaccine.2021.05.063 · DOI · Paper page
- Gao, 2022, Ancestral SARS-CoV-2-specific T cells cross-recognize the omicron variant, Nat Med, 28, 472, 10.1038/s41591-022-01700-x · DOI · Paper page
- Duarte, 2022, Adapting serosurveys for the SARS-CoV-2 vaccine era, Open Forum Infect Dis, 9, 10.1093/ofid/ofab632 · DOI
Cited by
Barber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00484-6 · Cited by 298
Levin, A. T., Owusu-Boaitey, N., Pugh, S., Fosdick, B. K., Zwi, A. B., Malani, A., Soman, S., Besançon, L., Kashnitsky, I., Ganesh, S., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008477 · Cited by 208
Metadata
- Authors
- Lewis, H. C., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., Cao, C., Yanes-Lane, M., Herring, B. L., Talisuna, A., Ngoy, N., Balde, T., Clifton, D., Van Kerkhove, M. D., Buckeridge, D., Bobrovitz, N., Okeibunor, J., Arora, R. K., & Bergeri, I.
- Venue
- BMJ Global Health
- Publisher
- BMJ
- Published
- 2022-08
- Volume
- 7
- Issue
- 8
- Pages
- e008793
- ISSN
- 2059-7908 (ISSN-L)
- OpenAlex
- W4292774342
- Cited by
- 173
- References
- 10
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- World Health Organization (WHO COVID-19 Solidarity Response Fund)
- Canadian Medical Association (Joule Innovation Fund)
- Bundesministerium für Gesundheit, Germany (COVID-19 Research and Development Fund)
- Robert Koch Institute Germany
- Public Health Agency of Canada (Canada’s COVID-19 Immunity Task Force)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. https://app.cochat.ai/papers/10.1136/bmjgh-2022-008793
- The paper
- Lewis, H. C., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., Cao, C., Yanes-Lane, M., Herring, B. L., Talisuna, A., Ngoy, N., Balde, T., Clifton, D., Van Kerkhove, M. D., Buckeridge, D., . . . Bergeri, I. (2022). SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Global Health. https://doi.org/10.1136/bmjgh-2022-008793
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.